Hetero, shahararriyar kungiyar harhada magunguna ta duniya tare da Shenzhen Beimei Pharmaceuticals tare sun sanar da cewa sun karbi lasisin shigo da magunguna na Oseltamivir phosphate a karkashin sunan Oselavir® daga hukumar kula da magunguna ta kasar Sin, hukumar kula da kayayyakin kiwon lafiya ta kasar (NMPA).
Oseltamivir phosphate magani ne na rigakafi da ake amfani da shi don maganin cututtukan mura maras rikitarwa a cikin manya, matasa da yara (≥2 makonni). Oselavir® za a yi samuwa a kasar Sin a cikin nau'i na sashi - 12.5ml: 75mg foda don dakatar da baki.
WHO ta kiyasta cewa mura na yanayi na iya haifar da mutuwar mutane 290,000-650,000 a kowace shekara saboda cututtukan numfashi kadai. Ƙididdigar ba ta la'akari da mace-mace daga wasu cututtuka kamar cututtukan zuciya da jijiyoyin jini, waɗanda ke da alaƙa da mura.1.
Dr. Vamsi Krishna Bandi, Manajan Darakta, Ƙungiyar Kamfanoni na Hetero Ya ce, "Mun yi farin ciki cewa Hetero tare da hadin gwiwar Shenzhen Beimei Pharmaceuticals na kasar Sin, sun sami amincewar Oselavir® (Oseltamivir) a kasar Sin. Wannan shi ne farkon amincewar samfurin Hetero a kasar Sin, kuma mun himmatu wajen kawo karin kayayyaki zuwa kasar Sin nan gaba."
Madam Guangmei Wu, Shugaba kuma Shugaba na Shenzhen Beimei Pharmaceuticals Ya ce, "Tare da amincewa da goyon bayan juna tsakanin kungiyoyin Beimei da Hetero, an kaddamar da Oselavir® a kasar Sin a matsayin na farko na kasar Sin da aka amince da samfurin Oseltamivir a cikin nau'i na musamman na yara. Ina nuna godiya ga ƙungiyar Hetero don aiki mai wuyar gaske da ƙoƙari a cikin dukan tsarin ci gaban samfur, aikace-aikacen rajista da ƙaddamar da shirye-shiryen Oselavir®. Muna sa ran bincika ƙarin samfuran tare da Hetero don kula da lafiyar yara na duniya a nan gaba. "
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- I express gratitude to the Hetero team for their hard work and effort in the whole process of product development, registration application and launch preparation for Oselavir®.
- Guangmei Wu, President and CEO of Shenzhen Beimei Pharmaceuticals said, “With mutual trust and support between Beimei and Hetero teams, Oselavir® was launched in China as the first Chinese approved Oseltamivir product in paediatric-specific dosage form.
- This is the first finished product approval for Hetero in China, and we are committed to bring more products to China in the near future.
